Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News SCYNEXIS Inc SCYX

Healthcare

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens,... see more

Add To Watchlist

Recent & Breaking News (NDAQ:SCYX)

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against SCYNEXIS, Inc. (SCYX) & Lead Plaintiff Deadline - May 8, 2017

PR Newswire March 14, 2017

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against SCYNEXIS, Inc. – SCYX

Business Wire March 14, 2017

SCYX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving SCYNEXIS, Inc. and a Lead Plaintiff Deadline of May 8, 2017

GlobeNewswire March 14, 2017

SCYNEXIS Reports Full Year 2016 Financial Results and Provides Company Update

GlobeNewswire March 13, 2017

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against SCYNEXIS, Inc. (SCYX)

GlobeNewswire March 10, 2017

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of SCYNEXIS, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 8, 2017 – SCYX

GlobeNewswire March 10, 2017

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against SCYNEXIS, Inc. and Certain Officers – SCYX

GlobeNewswire March 8, 2017

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of SCYNEXIS, Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire March 7, 2017

SCYNEXIS, Inc. to Present at the 29th Annual ROTH Conference

GlobeNewswire March 7, 2017

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of SCYNEXIS, Inc. (SCYX)

PR Newswire March 6, 2017

SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of SCYNEXIS, Inc. and Advises Investors with Losses to Contact the Firm

Business Wire March 3, 2017

Mid-Afternoon Market Update: Immersion Drops After Q4 Results; Snap Shares Spike Higher

Benzinga.com March 3, 2017

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of SCYNEXIS, Inc. -- SCYX

Business Wire March 3, 2017

15 Biggest Mid-Day Losers For Friday

Benzinga.com March 3, 2017

Mid-Day Market Update: Nutanix Drops On Weak Guidance; BioScrip Shares Climb

Benzinga.com March 3, 2017

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX

PR Newswire March 3, 2017

Mid-Morning Market Update: Markets Edge Lower; Big Lots Profit Beats Estimates

Benzinga.com March 3, 2017

SCYNEXIS delays initiation of new clinical studies using the IV formulation of SCY-078 at FDA’s request

GlobeNewswire March 2, 2017

How These Generic Drugs Stocks are Faring? -- Neurocrine Biosciences, Evoke Pharma, SCYNEXIS, and Eagle Pharma

PR Newswire February 3, 2017

SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences

GlobeNewswire January 31, 2017